Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

SSG&PM (VL)


An Improved Treatment Option for Visceral Leishmaniasis available since 2010!

Main Advantages of SSG&PM
 
  • SSG&PM has been shown in clinical trials to be as safe and effective as the current standard treatment of SSG alone for 30 days in East Africa.
  • SSG&PM offers a real cost effective option
    • The total drug cost of the SSG&PM combination is lower than the cost of SSG alone (44 vs 56 USD).
    • SSG&PM has a significantly shorter treatment duration than that of the standard treatment (17 days versus 30 days).
    • Reduction of treatment duration means cost savings to both health providers and patients.
    • Reduction of treatment duration is also critical to increasing patient turnover during outbreaks.
  • The combination of SSG&PM has the potential to prolong the life of both drugs.


A Collaborative Partnership

The development of SSG&PM is the result of a collaborative partnership over a period of six years that reflects the benefits of South-South and North-South collaboration in making a new treatment available to patients in need. Partners include

  • DNDi
  • the Leishmaniasis East Africa Platform (LEAP)
  • the National Control Programmes of Kenya, Sudan, Ethiopia, and Uganda
  • Médecins Sans Frontières (MSF)
  • The World Health Organization (WHO)

Download SSG&PM complete brochure (05/2011) [PDF 500KB]
Read more about SSG&PM project

   
  SSG&PM News

Lemarus Tebawani Lukero is a 23 years old Kenyan who has been suffering from VL for 2 years and is treated with SSG&PM. Read his story.

Implementation has commenced in Sudan and South Sudan

PLOS NTDs, June 2012
Sodium Stibogluconate (SSG) & Paramomycin combination compared to SSG for visceral leishmaniasis in East Africa: A randomised controlled trial.

October 2011
During the LEAP meeting in Nairobi, DNDi hold a press conference on SSG&PM launch.

Read Press release
Listen to DNDi Medical Director presenting the treatment
Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License